Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.
Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA. Gerber DE, et al. Among authors: fattah f. Br J Cancer. 2018 Oct;119(8):928-936. doi: 10.1038/s41416-018-0278-4. Epub 2018 Oct 15. Br J Cancer. 2018. PMID: 30318513 Free PMC article. Clinical Trial.
Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, Morales JC, Motea EA, Bornmann WG, Yordy JS, Boothman DA. Cao L, et al. Among authors: fattah f. Antioxid Redox Signal. 2014 Jul 10;21(2):237-50. doi: 10.1089/ars.2013.5462. Epub 2014 Apr 3. Antioxid Redox Signal. 2014. PMID: 24512128 Free PMC article.
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH. Gerber DE, et al. Lung Cancer. 2015 Dec;90(3):534-41. doi: 10.1016/j.lungcan.2015.10.008. Epub 2015 Oct 9. Lung Cancer. 2015. PMID: 26474959 Free PMC article. Clinical Trial.
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA. Huang X, et al. Among authors: fattah f. Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006. Cancer Cell. 2016. PMID: 27960087 Free PMC article.
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA. Beg MS, et al. Among authors: fattah f. J Surg Oncol. 2017 Jul;116(1):83-88. doi: 10.1002/jso.24624. Epub 2017 Mar 27. J Surg Oncol. 2017. PMID: 28346693 Free PMC article.
103 results